Palivizumab is a humanized IgG1 monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV).
This humanized monoclonal antibody is composed of 95% human and 5% murine amino acid sequences. Palivizumab is composed of two heavy chains and two light chains having a molecular weight of approximately 148,000 Daltons.
Palivizumab is supplied as a sterile solution for intramuscular injection. Palivizumab contains the following excipients: 25 mM histidine and 1.6 mM glycine and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL.